N-terminal 16K fragments of the human prolactin/growth hormone family are known to be potential angiogenesis inhibitors. Lately, structurally-related peptides, based on a tilted peptide structure, have been identified by a Belgian University as angiogenic inhibitors.

The University is looking for cooperation with an academic institution or for a licence agreement with a pharmaceutical company for further development.